The distribution according to the tumor phenotypes of the second metastasis was: HR-positive without HER2 amplification or overexpression 50% (n = 33), triple negative 18.2% (n = 12), and HER-2 positive 31.8% (n = 21). The gene discussed is ERBB2; the disease is neoplasm.